Response to Letter: ‘Reply to 'High frequency of antiphospholipid antibodies in critically ill COVID‐19 patients: a link with hypercoagulability?'’

We read with great interest the comment by Suarez-Perez et al. on our article.[1] We share their concerns regarding the need for a cautious interpretation of antiphospholipid antibodies (aPLA) positivity in patients with coronary virus disease 2019 (COVID-19). Herein, we would like to add further insights in the discussion.